Literature DB >> 24303474

Synchronous rectal and esophageal cancer treated with chemotherapy followed by two-stage resection.

Setsuo Utsunomiya1, Keisuke Uehara, Takuya Kurimoto, Ken Hirose, Masahide Fukaya, Yu Takahashi, Yoshiro Taguchi, Keita Itatsu, Masato Nagino.   

Abstract

We report a case of 61-year-old male who had synchronous advanced rectal cancer involving the urinary bladder massively associated with multiple liver metastases, and esophageal cancer successfully treated by neoadjuvant chemotherapy followed by two-stage resection. Although complete resection of each of the lesions was considered possible by performing anterior pelvic exenteration, liver resection, and esophagectomy, it might be impossible for the patient to endure the stress of all of these operative procedures at once. Therefore, we planned to perform staged treatment with prioritizing consideration. First, we instituted chemotherapy with the FOLFOX (oxaliplatin + fluorouracil + leucovorin) plus cetuximab regimen, which could adequately control both rectal and esophageal cancer. After 6 cycles of chemotherapy, high anterior resection combined with cystoprostatectomy and lateral segmentectomy plus partial hepatectomy was performed followed by staged esophagectomy with three-field lymph node dissection. It was possible to use oxaliplatin and cetuximab safely as neoadjuvant therapy not only for advanced rectal cancer but for esophageal cancer, and it was effective.

Entities:  

Keywords:  Cetuximab; Esophageal cancer; Neoadjuvant chemotherapy; Oxaliplatin; Rectal cancer

Year:  2013        PMID: 24303474      PMCID: PMC3845935          DOI: 10.12998/wjcc.v1.i2.87

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  10 in total

1.  Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients.

Authors:  Hari Nathan; Mechteld C de Jong; Carlo Pulitano; Dario Ribero; Jennifer Strub; Gilles Mentha; Jean-François Gigot; Richard D Schulick; Michael A Choti; Luca Aldrighetti; Lorenzo Capussotti; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2010-05       Impact factor: 6.113

2.  A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).

Authors:  Nobutoshi Ando; Hoichi Kato; Hiroyasu Igaki; Masayuki Shinoda; Soji Ozawa; Hideaki Shimizu; Tsutomu Nakamura; Hiroshi Yabusaki; Norio Aoyama; Akira Kurita; Kenichiro Ikeda; Tatsuo Kanda; Toshimasa Tsujinaka; Kenichi Nakamura; Haruhiko Fukuda
Journal:  Ann Surg Oncol       Date:  2011-08-31       Impact factor: 5.344

3.  Prognostic evaluation of patients with clinical T1 and T2 squamous cell carcinomas of the thoracic esophagus after 3-field lymph node dissection.

Authors:  Hiroyasu Igaki; Hoichi Kato; Yuji Tachimori; Yukihiro Nakanishi
Journal:  Surgery       Date:  2003-04       Impact factor: 3.982

4.  Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus.

Authors:  A M Mauer; E H Kraut; S A Krauss; R H Ansari; K Kasza; L Szeto; E E Vokes
Journal:  Ann Oncol       Date:  2005-05-26       Impact factor: 32.976

5.  Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer.

Authors:  Tian-Jie Qin; Gai-Li An; Xin-Han Zhao; Fang Tian; Xiao-Hua Li; Juan-Wen Lian; Bo-Rong Pan; Shan-Zhi Gu
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

6.  Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.

Authors:  Gunnar Folprecht; Thomas Gruenberger; Wolf O Bechstein; Hans-Rudolf Raab; Florian Lordick; Jörg T Hartmann; Hauke Lang; Andrea Frilling; Jan Stoehlmacher; Jürgen Weitz; Ralf Konopke; Christian Stroszczynski; Torsten Liersch; Detlev Ockert; Thomas Herrmann; Eray Goekkurt; Fabio Parisi; Claus-Henning Köhne
Journal:  Lancet Oncol       Date:  2009-11-26       Impact factor: 41.316

7.  Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute.

Authors:  Masaru Morita; Rintaro Yoshida; Keisuke Ikeda; Akinori Egashira; Eiji Oki; Noriaki Sadanaga; Yoshihiro Kakeji; Takeharu Yamanaka; Yoshihiko Maehara
Journal:  Surgery       Date:  2008-03-04       Impact factor: 3.982

8.  Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.

Authors:  S Lorenzen; T Schuster; R Porschen; S-E Al-Batran; R Hofheinz; P Thuss-Patience; M Moehler; P Grabowski; D Arnold; T Greten; L Müller; N Röthling; C Peschel; R Langer; F Lordick
Journal:  Ann Oncol       Date:  2009-06-23       Impact factor: 32.976

9.  First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study.

Authors:  E van Meerten; F A L M Eskens; E C van Gameren; L Doorn; A van der Gaast
Journal:  Br J Cancer       Date:  2007-04-17       Impact factor: 7.640

10.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.